Navigation Links
The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
Date:6/10/2008

WHITE PLAINS, N.Y., June 10 /PRNewswire/ -- Provid Pharmaceuticals, Inc. and The Leukemia & Lymphoma Society (LLS) today jointly announced the execution of a research agreement to advance the development of a treatment for acute myelogenous leukemia.

Under the arrangement, LLS has contracted with Provid to supply expert medicinal chemistry services in support of an LLS-funded Specialized Center of Research (SCOR) grant at the University of Virginia under the direction of Prof. John Bushweller, Ph.D.

"Provid's expertise adds a critical component to our SCOR program that will help advance our efforts from 'interesting laboratory results' to potential therapies," said Dr. Bushweller.

Louis J. DeGennaro, Ph.D., Chief Scientific Officer of LLS, added, "Our partnership with Provid is the result of a detailed selection process to identify companies that have significant drug discovery experience and fills a critical need for medicinal chemistry expertise. We believe that working with Provid will advance our research programs and speed effective therapies to our patients."

"As a company that applies medicinal chemistry expertise to transform biological discoveries into valuable drug leads, we are enthusiastic to work closely with LLS and Dr. Bushweller in the field of blood cancers," said Dr. Gary Olson, Chief Executive Officer of Provid. "We will dedicate our experienced team to this project to accelerate the validation and translation of research results from the Bushweller lab into potential leads for drug development."

The Provid partnership marks the first project of the Academic Concierge Division announced under LLS's Therapy Acceleration Program (TAP). This innovative program is designed to leverage current academic research investments by providing investigators access to the same expertise and services that pharmaceutical companies utilize. The ultimate goal of all TAP contracts is to advance therapies for patients suffering from blood cancers.

About Provid Pharmaceuticals Inc.

Provid is a drug discovery service company located in North Brunswick, New Jersey, that provides expert medicinal chemistry support to biotech and pharmaceutical industries, and to government labs, research foundations, and academic groups. The company also uniquely offers experimental due diligence (EXPEDD(TM)) to support decisions by academic technology transfer teams, venture investors, pharma and biotech portfolio management groups. The company has a strategic alliance with iNovacia AB in Stockholm that extends drug discovery capabilities via assay development, screening, and biophysical characterization. For more information, see http://www.providpharma.com.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the LLS Information Resource Center (IRC), a call center staffed by master's level social workers and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif

914.821.8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
6. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
9. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
10. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
11. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016 Beike Biotechnology, the ... attended a ceremony in late 2015 to mark their ... in 2016. --> --> ... for Personalized Cell Therapy" was hosted by the Shenzhen ... both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... YORK , February 4, 2016 ... QBIO), a biotechnology acceleration company is pleased to provide the ... --> Over the last 3 months we ... and securities purchase agreements exceeding $1,000,000. As a result, we ... our Mannin Research Inc. license agreement and expect that development ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") ... products in China , today announced ... received on February 4, 2016 a preliminary non-binding proposal ... of PKU V-Ming ( Shanghai ) Investment ... Development ( Shenzhen ) Fund Management Co., ...
(Date:2/4/2016)... ... February 04, 2016 , ... Many of the engineers at ... years. What sets them apart from other cuvette manufacturers is their supercharged customer ... website. On top of this steady flow of inside information, they have recently ...
Breaking Biology Technology:
(Date:1/20/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce the attainment of record-setting ... result of the company,s laser focus on (and growing ... it,s comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... MedNet growth achievements in 2015 include: , ...
(Date:1/13/2016)... January 13, 2016 ... addition of the  "India Biometrics Authentication ... Forecast (2015-2020)"  report to their ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC Research ... for biometric technologies and devices, identifying newer markets and ... various types of biometric devices. Includes forecast from 2015 ... Identify newer markets and explore the expansion of the ... Examine each type of biometric technology, determine its current ...
Breaking Biology News(10 mins):